financetom
Business
financetom
/
Business
/
Exclusive | Zuari Agro in talks to sell Mangalore Chemicals stake to Paradeep Phosphates: Sources
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Exclusive | Zuari Agro in talks to sell Mangalore Chemicals stake to Paradeep Phosphates: Sources
Jul 12, 2023 6:18 AM

In a large deal brewing in the chemicals & fertilisers sector, Saroj Poddar-led Adventz Group is looking at reorganisation of its assets within the promoter group. Sources with direct knowledge said that Zuari Agro Chemicals, parent of Mangalore Chemicals, is in talks with another group company Paradeep Phosphates to sell its stake in subsidiary Mangalore Chemicals.

Share Market Live

NSE

Zuari Agro had bought Mangalore Chemicals in 2015 and is now looking to sell shares and majority control to raise funds to repay debt, sources suggest. Sources said, "Deal options include merging Mangalore Chemicals with Paradeep Phosphates."

Zuari Agro currently owns 54 percent stake in Mangalore Chemicals. Kolkata-based, Saroj Poddar is at the helm of the promoter group which owns Zuari Agro, Chambal Fertilisers and Mangalore Chemicals.

Paradeep Phosphates (PPL) is owned by Zuari Maroc Phosphates Pvt. Ltd. (ZMPPL), a joint venture between Zuari Agro Chemicals Limited (ZACL) and the OCP Group S.A. PPL completed its Rs 1500 crore initial public offering (IPO) last year. The company also used part of the proceeds to complete the acquisition of the 1.2 million MT fertilizer plant in Goa in June 2022. Post IPO, ZMPPL holds 56.10 percent in PPL.

Earlier, Zuari Agro was exploring the same deal with Chambal Fertilisers but aborted the plan as the deal was less tax efficient, sources indicate. Adventz Group did not offer a comment on queries regarding the deal talks.

The shares of Zuari Agro has been on a rise since April. The share price has increased from Rs 116 to Rs 174, witnessing a rise of 31 percent in three months, and 75 percent in three years. The share price of Paradeep Phosphate is at a price of Rs.63. It has increased by 12 percent in one month, 18 percent in 3 months and 50 percent in one year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US regional banks to face increased scrutiny as CRE exposure stifles buybacks
US regional banks to face increased scrutiny as CRE exposure stifles buybacks
Jul 10, 2024
(Reuters) - U.S. regional banks will probably stockpile more rainy-day funds and stay conservative on stock buybacks as losses from commercial real estate (CRE) loans are expected to pressure their earnings, analysts said. As regional lenders prepare to report second-quarter results next week, they continue to face tough scrutiny from investors over potential weakness from CRE and commercial borrowers. Regional...
Virpax Says Non-Narcotic Pain Medication Shows Positive Results in Swine Model Study; Shares Rise
Virpax Says Non-Narcotic Pain Medication Shows Positive Results in Swine Model Study; Shares Rise
Jul 10, 2024
08:34 AM EDT, 07/10/2024 (MT Newswires) -- Virpax Pharmaceuticals ( VRPX ) on Wednesday reported positive results in a swine model pilot study of Probudur, the company's liposomal bupivacaine formulation to provide both immediate and extended pain relief. Probudur was injected into four juvenile domestic pigs at a dose of 30 mg per kilogram and was well-tolerated and demonstrated a...
--HSBC Gets SVB Trade-Secret Lawsuit Trimmed Down
--HSBC Gets SVB Trade-Secret Lawsuit Trimmed Down
Jul 10, 2024
08:35 AM EDT, 07/10/2024 (MT Newswires) -- Price: 43.01, Change: +0.03, Percent Change: +0.07 ...
Kazia Therapeutics' Phase 2/3 Trial for Paxalisib in Glioblastoma Brain Cancer Shows Clinically Significant Improvement
Kazia Therapeutics' Phase 2/3 Trial for Paxalisib in Glioblastoma Brain Cancer Shows Clinically Significant Improvement
Jul 10, 2024
08:32 AM EDT, 07/10/2024 (MT Newswires) -- Kazia Therapeutics ( KZIA ) said Wednesday a phase 2/3 trial has shown that its investigational brain disease treatment, paxalisib, causes clinically significant improvement in overall survival for patients with glioblastoma, a life-threatening brain cancer. Paxalisib showed an approximate 33% improvement in the overall survival of newly diagnosed patients with glioblastoma, compared with...
Copyright 2023-2026 - www.financetom.com All Rights Reserved